Streetbeat News

Products Services

RDHL

RedHill Biopharma shares are trading higher after the company announced a new publication showing that triple antimicrobial therapy with RHB-104 plus standard of care is 64% more effective than standard of care alone in treating Crohn's disease.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:45 am

RDHL

RedHill Biopharma announced new data showing that its triple antimicrobial therapy RHB-104, combined with standard care, is 64% more effective than standard care alone in treating Crohn's disease.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:43 am

ACB

Aurora Cannabis and Vectura Fertin Pharma have announced a commercial collaboration with Cogent International Manufacturing to launch a CBD lozenge on Aurora's Canadian medical cannabis platform. The agreement has an initial term of 24 months, with the first product expected to launch in late 2024.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:40 am

AER

AerCap has delivered the first three of fifteen new Airbus A321neo aircraft to AirAsia on a long-term lease.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:17 am

PASG

Passage Bio (NASDAQ:PASG) has out-licensed three pediatric lysosomal storage disease programs to GEMMA Biotherapeutics for $20M in initial payments and up to $114M in milestones, plus future royalties. GEMMABio will assume financial obligations and Passage Bio will support the transition.

Portfolio Pulse from charles@benzinga.com

August 01, 2024 | 11:13 am

GLD

QQQ

SPY

UUP

On July 31, U.S. stock markets closed higher with significant gains in the S&P 500 and Nasdaq, driven by a rally in chip stocks and the Federal Reserve's decision to keep interest rates unchanged. U.S. pending home sales rose 4.8% in June, and private businesses added 122,000 jobs in July. In Asia, Japan's Nikkei 225 fell sharply due to a hawkish stance from the BOJ, while Australia's S&P/ASX 200 and India's Nifty 50 saw gains. European markets declined, and commodities like gold and crude oil saw price increases. The U.S. dollar strengthened.

Portfolio Pulse from Akanksha Bakshi

August 01, 2024 | 10:52 am

LLY

Eli Lilly's SUMMIT Phase 3 trial of Tirzepatide for heart failure with preserved ejection fraction and obesity showed statistically significant improvements in reducing heart failure outcomes and physical limitations.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:50 am

MBLY

ZK

Zeekr and Mobileye have announced plans to accelerate technology localization in China, integrating Mobileye's technologies into Zeekr's next-generation models. This collaboration aims to enhance driving safety and automation both in China and globally.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:44 am

AULT

Ault Alliance plans to issue special dividends to stockholders of its subsidiaries not related to its AI data center business. Hyperscale Data will focus on leveraging its data center assets in Michigan and Montana to capitalize on the growing AI and data center markets in the U.S.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:39 am

MRNA

Moderna has revised its 2024 expected net product sales from its respiratory franchise to $3B-$3.5B, down from prior guidance of $4B. The revision is due to low EU sales, potential revenue deferrals, and increased competition in the U.S. Cost of sales is expected to be 40-50% of product sales, with R&D expenses at $4.5B, SG&A expenses at $1.3B, and capital expenditures at $0.9B. Year-end cash and investments are projected to be $9B.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:39 am